Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, has announced the pricing of an underwritten public offering of 10,256,411 shares of its common stock, offered at a public offering price of US$9.75 per share. In addition, Cogent Biosciences has granted the underwriters a 30-day option to purchase up to an additional 1,538,461 shares of its common stock at the public offering price less underwriting discounts. The size of the offering was upsized from US$60 million to approximately US$100 million. All of the shares of common stock sold in the offering are being sold by Cogent Biosciences. The offering is expected to close on or about December 4, 2020, subject to customary closing conditions.
Latham & Watkins LLP represented the underwriters in the offering with a capital markets team led by New York partner Nathan Ajiashvili, with New York associates Roger Yarett, Victoria McGrath, and Isabelle Sawhney.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.